Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer

Journal of Clinical Pathology

Volumn 61, Issue 4, 2008, Pages 448-454

  Wako, Koichi ^a   Kawasaki, T ^a   Yamana, K ^a   Suzuki, K ^a   Jiang, S ^a,b   Umezu, H ^a   Nishiyama, T ^a   Takahashi, K ^a   Hamakubo, T ^c   Kodama, T ^c   Naito, M ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b Perseus Proteomics   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDO KETO REDUCTASE 1C3; ANDROGEN RECEPTOR; OXIDOREDUCTASE; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

3-HYDROXYSTEROID DEHYDROGENASES; ADULT; AGED; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TESTOSTERONE 5-ALPHA-REDUCTASE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 42049098597     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2007.050906     Document Type: Article

References (35)

1. In: Tajima K, Kuroishi T, Oshima A, eds. The research group for population-based cancer registration in Japan: cancer incidence in Japan. Cancer mortality and morbidity statistics: Japan and the world, 2004. Tokyo: Japan Scientific Societies Press, 2004:95-130.
2. Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol Cell Biochem 2003;253:89-101.
3. Labrie F, Dupont A, Giguere M, et al. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer. J Steroid Biochem 1986;25:877-83.
4. Geller J, Albert J, Vik A. Advantages of total androgen blockade in the treatment of advanced prostate cancer. Semin Oncol 1988;15:53-61.
5. Belanger B, Belanger A, Labrie F, et al. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem 1989;32:695-8.
6. Labrie F, Belanger A, Dupont A, et al. Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 1993;16:475-92.
7. Li R, Wheeler T, Dai H, et al. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004;28:928-34.
8. Inoue T, Segawa T, Shiraishi T, et al. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 2005;66:332-7.
9. Russell DW, Wilson JD. Steroid 5α-reductase: two genes/two enzymes. Annu Rev Biochem 1994;63:25-61.
10. Bonkhoff H, Sein U, Aumuller G, et al. Differential expression of 5α-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 1996;29:261-7.
11. Thomas LN, Douglas RC, Vessey JP, et al. 5α-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol 2003;170:2019-25.
12. Lin HK, Jez JM, Schlegel BP, et al. Expression and characterization of recombinant type 2 3α-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3α/17 beta-HSD activity and cellular distribution. Mol Endocrinol 1997;11:1971- 84.
13. El-Alfy M, Luu-The V, Huang XF, et al. Localization of type 5 17β-hydroxysteroid dehydrogenase, 3β-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology 1999;140:1481-91.
14. Penning TM, Burczynski ME, Jez JM, et al. Structure-function aspects and inhibitor design of type 5 17β- hydroxysteroid dehydrogenase (AKR1C3). Mol Cell Endocrinol 2001;171:137-49.
15. Lin HK, Steckelbroeck S, Fung KM, et al. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 2004;69:795-801.
16. Fung KM, Samara EN, Wong C, et al. Increased expression of type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 2006;13:169-80.
17. Albertsen PC, Fryback DG, Storer BE, et al. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995;274:626-31.
18. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-51.
19. Chan TY, Partin AW, Walsh PC, et al. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 2000;56:823-7.
20. Herman CM, Kattan MW, Ohori M, et al. Primary Gleason pattern as a predictor of disease progression in gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy. Am J Surg Pathol 2001;25:657-60.
21. Oshima T, Kawasaki T, Ohashi R, et al. Down-regulated P1 promoter-driven HNF4α expression in human colorectal carcinoma is a new prognostic factor against liver metastasis. Path Int 2007;57:82- 90.
22. Ahlering TE, Skarecky DW, McLaren CE, et al. Seminal vesicle involvement in patients with D1 disease predicts early prostate specific antigen recurrence and metastasis after radical prostatectomy and early androgen ablation. Cancer 2002;94:1648-53.
23. Daneshmand S, Quek ML, Stein JP, et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004;172:2252-5.
24. Gregory CW, Johnson RT Jr, Mohler JL, et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61:2892-8.
25. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
26. Gregory CW, He B, Johnson RT, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315-9.
27. Agoulnik IU, Vaid A, Bingman WE 3rd, et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 2005;65:7959-67.
28. Zhou HJ, Yan J, Luo W, et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 2005;65:7976-83.
29. Thomas LN, Lazier CB, Gupta R, et al. Differential alterations in 5α-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005;63:231-9.
30. Titus MA, Gregory CW, Ford OH 3rd, et al. Steroid 5α-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005;11:4365-71.
31. Luo J, Dunn TA, Ewing CM, et al. Decreased gene expression of steroid 5α-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 2003;57:134-9.
32. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
33. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.
34. Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 2004;10:7121-6.
35. Suzuki K, Nishiyama T, Hara N, et al. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis 2007;10:301-6.